YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation
Journal of Clinical Investigation · 16.01.2025 · 135 (2)
DOI: 10.1172/jci171164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 21.11.2024. Verfasst von Pritam Sadhukhan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery and. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Urinary Bladder Neoplasms, Interleukin-6, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
The Hippo signaling pathway plays a key role in tumorigenesis in different cancer types. We investigated the role of the Hippo effector YAP1 in the tumor immune microenvironment (TIME) of urothelial carcinoma of the bladder (UCB) and evaluated the efficacy of immunotherapy in the context of YAP1 signaling. We performed numerous in vitro and in vivo experiments to determine the role of YAP1 using genetic and pharmacological attenuation of YAP1 activity. Briefly, RNA sequencing was carried out with mouse and human cell lines to identify novel YAP1-regulated downstream targets unbiasedly. We then experimentally confirmed that YAP1 regulates the TIME through the IL-6/STAT3 signaling pathway and varied C-X-C motif chemokine regulation. We analyzed several human sample sets to explore the TIME status in the context of YAP1 expression. Our data indicate that YAP1 attenuation decreases M2 macrophages and myeloid-derived suppressor cells in the TIME compared with YAP1-expressing cells. In summary, this study provides insights into YAP1 signaling as a driver for cancer stemness and an inducer of immunosuppressive TIME. Moreover, the therapeutic efficacy of YAP1 attenuation indicates that combined blockade of YAP1 and immune checkpoints may yield clinical value for treating patients with UCB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery and.
- Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Champions Oncology, R&D, Baltimore, Maryland, USA.
- Department of Pathology and.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Förderung
- NCI NIH HHS
- NIEHS NIH HHS
Zitieren
APA
Sadhukhan, P., Feng, M., Illingworth, E., Sloma, I., Ooki, A., Matoso, A., Sidransky, D., Johnson, B. A., Marchionni, L., Sillé, F. C., Choi, W., McConkey, D., & Hoque, M. O. (2025). YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation. Journal of Clinical Investigation, 135(2). https://doi.org/10.1172/jci171164
Vancouver
Sadhukhan P, Feng M, Illingworth E, Sloma I, Ooki A, Matoso A, et al. YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation. Journal of Clinical Investigation. 2025;135(2). doi:10.1172/jci171164
BibTeX
@article{Sadhukhan2025,
author = {Sadhukhan, Pritam and Feng, Mingxiao and Illingworth, Emily and Sloma, Ido and Ooki, Akira and Matoso, Andres and Sidransky, David and Johnson, Burles A and Marchionni, Luigi and Sillé, Fenna Cm and Choi, Woonyoung and McConkey, David and Hoque, Mohammad O},
title = {YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {2},
doi = {10.1172/jci171164}
}
EUVIMED